Prolonged compound muscle action potential duration in critical illness Myopathy: Report of nine cases

Journal of Clinical Neuromuscular Disease

Volumn 5, Issue 4, 2004, Pages 176-183

  Park, Edward J ^a   Nishida, Takashi ^b,c   Sufit, Robert L ^b   Minieka, Michael M ^b  

^a REHABILITATION INSTITUTE OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Compound muscle action potential; Corticosteroid; Critical illness myopathy; Duration

Indexed keywords

BLEOMYCIN; CORTICOSTEROID DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ELECTROMYOGRAPHY; FEMALE; HEALTH CARE FACILITY; HUMAN; INTENSIVE CARE UNIT; LUNG HEMORRHAGE; LUNG TOXICITY; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; MYOPATHY; PERONEUS NERVE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPSIS; TIBIAL NERVE; ULNAR NERVE;

EID: 3042703042     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet. 1977;2:615.
2. Hirano M, Ott BR, Raps EC, et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 1992;32:2082-2087.
3. Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve. 2000;23:1785-1788.
4. Sliwa JA. Acute weakness syndromes in the critically ill patient. Arch Phys Med Rehabil. 2000;81: s45-s52.
5. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med. 1996;24:1408-1416.
6. Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during corticosteroid treatment. Muscle Nerve. 1991;14:1131-1139.
7. Faragher MW, Day BJ, Dennett X. Critical care myopathy: an electrophysiological and histological study. Muscle Nerve. 1996;19:516-518.
8. Lacomis D, Giuliani MJ, Cott AV, et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40: 645-654.
9. Minetti C, Hirano M, Morreale G, et al. Ubiquitin expression in acute steroid myopathy with loss of myosin thick filaments. Muscle Nerve. 1996;19: 94-96.
10. Ramsay DA, Zochodne DW, Robertson DM, et al. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol. 1993;52:387-398.
11. Rich MM, Teener JW, Raps EC, et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology. 1996;46:731-736.
12. Sander HW, Golden M, Danon MJ. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve. 2002;26: 499-505.
13. Scully RE, Mark EJ, McNeely WF, et al. Case 11 - 1997. N Engl J Med. 1997;336:1079-1088.
14. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve. 1997; 20:316-322.
15. Kurokawa K, Mimori Y, Tanaka E, et al. Age-related change in peripheral nerve conduction: compound muscle action potential duration and dispersion. Gerontology. 1999;45:168-173.
16. Zochodne DW, Ramsay DA, Saly V, et al. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve. 1994;17:285-292.
17. Deconinck N, Van Parijs V, Beckers-Bleukx G, et al. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord. 1998;8:186-192.
18. Dover M, Weiner L, Gooch C. Direct muscle stimulation in acute and chronic neurogenic disease. Muscle Nerve. 2003;12(suppl):3.
19. Carpenter S, Karpati G. Pathology of Skeletal Muscle. New York: Churchill and Livingstone; 1984:220-221
20. Yarom R, Sphira Y. Myosin degeneration in a congenital myopathy. Arch Neurol. 1977;34:114-115.
21. Trojaborg W, Weimer LH, Hays AP. Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy - a reappraisal. Clin Neurophysiol. 2001;112:1586-1593.
22. Singleton JR, Baker BL, Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology. 2000; 141:2945-2950.
23. Massa R, Carpenter S, Holland P, et al. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve. 1992;15:1290-1298.
24. Rouleau G, Karpati G, Carpenter S, et al. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve. 1987;10:428-438.
25. Dubois DC, Almon RR. A possible role for glucocorticoids in denervation atrophy. Muscle Nerve. 1981; 4:370-373.
26. De Letter MA, van Doorn PA, Savelkoul HF, et al. Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol. 2000;106:206-213.
27. Lee TS, Nishida T. Critical illness myopathy: unusual electrophysiologic findings. Arch Phys Med Rehabil. 2000;81:1304.
28. Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002;59:1526-1532.
29. Bolton CF, Sawa GM, Carter K. The effect of temperature on human compound muscle action potentials. J. Neurol Neurosurg Psychiatry. 1981;44:407-413.
30. Rich MM, Pinter MJ. Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol. 2001;50:26-33.